Cases & Deals

  • Home
  • Practices
  • BioMarin expands rare disease oligonucleotide therapeutic patent portfolio following worldwide settlement with Sarepta

Share

BioMarin expands rare disease oligonucleotide therapeutic patent portfolio following worldwide settlement with Sarepta

February 2018

Client(s) BioMarin Pharmaceutical Inc.

Jones Day represents BioMarin Pharmaceutical Inc. in prosecution of patent portfolio directed to oligonucleotide therapeutic agents for treatment of rare genetic diseases, including Duchenne Muscular Dystrophy and Becker Muscular Dystrophy. BioMarin recently entered into a worldwide settlement with Sarepta regarding patent disputes related to this portfolio.

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.